News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Pharmaceuticals progresses towards clinical-stage status with Phase I/IIa trial announcement on Ketamir-2, a novel oral ketamine analog, for pain management. CHDR's PainCart technology leveraged -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
MIRA Pharmaceuticals announces promising preclinical results for Ketamir-2, a potential breakthrough therapy surpassing current treatments. Study shows 60% greater efficacy than gabapentin in reducing chemotherapy-induced pain, to be presented at Pain Therapeutics Summit -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD -
